SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm today announced that the National Cancer Institute (NCI), the U.S. Government's principal agency for cancer research, is using Fluidigm’s BioMark™ System for Genetic Engineering to conduct rapid, cost-effective follow up to its whole-genome SNP association scans.
